Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.059
Buy
RSI(14)
57.904
Neutral
STOCH(KDJ)(9,3,3)
53.659
Sell
ATR(14)
0.266
High Vlolatility
CCI(14)
10.278
Neutral
Williams %R
49.231
Neutral
TRIX(12,20)
2.050
Buy
StochRSI(14)
7.413
Oversold
Search
Pyxis Oncology Inc
PYXSAdd to Watchlist
2.280USD
+0.070+3.17%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
144.45MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Pyxis Oncology Inc
Currency: USD Updated: 2026-05-15Key Insights
Pyxis Oncology Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 90 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 6.78.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Pyxis Oncology Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Pyxis Oncology Inc Highlights
StrengthsRisks
Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.
Growing
The company is in a growing phase, with the latest annual income totaling USD 13.86M.
Fairly Valued
The company’s latest PE is -1.75, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 25.75M shares, decreasing 34.52% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 728.38K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.24.
Analyst Rating
Based on
10
analysts
Strong Buy
Current Rating
6.778
Target Price
+206.69%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Pyxis Oncology Inc is 7.22, ranking 110 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.
Score
Financials
5.64
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.13
Operational Efficiency
4.76
Growth Potential
10.00
Shareholder Returns
7.58
Pyxis Oncology Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Pyxis Oncology Inc is 7.24, ranking 135 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.75, which is -78.45% below the recent high of -0.38 and -155.47% above the recent low of -4.48.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 90/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Pyxis Oncology Inc is 8.89, ranking 37 out of 382 in the Biotechnology & Medical Research industry. The average price target is 7.70, with a high of 9.00 and a low of 5.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
10
analysts
Strong Buy
Current Rating
6.778
Target Price
+206.69%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Pyxis Oncology Inc
PYXS
10
CRISPR Therapeutics AG
CRSP
27
Beigene Ltd
ONC
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Pyxis Oncology Inc is 7.45, ranking 64 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.93 and the support level at 1.63, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
2.492
Sell
MA10
2.335
Sell
MA20
2.040
Buy
MA50
1.729
Buy
MA100
1.596
Buy
MA200
2.226
Buy
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Pyxis Oncology Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 40.97%, representing a quarter-over-quarter increase of 2.86%. The largest institutional shareholder is James Simons, holding a total of 888.68K shares, representing 1.41% of shares outstanding, with 50.45% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Pyxis Oncology Inc is 1.47, ranking 298 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.48. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.51
VaR
--
240-Day Maximum Drawdown
+80.15%
240-Day Volatility
+120.30%
Return
Best Daily Return
60 days
+25.68%
120 days
+25.68%
5 years
--
Worst Daily Return
60 days
-15.65%
120 days
-48.66%
5 years
--
Sharpe Ratio
60 days
+2.46
120 days
-0.31
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+80.15%
3 years
+86.69%
5 years
--
Return-to-Drawdown Ratio
240 days
+1.08
3 years
-0.05
5 years
--
Skewness
240 days
-0.52
3 years
-0.26
5 years
--
Volatility
Realised Volatility
240 days
+120.30%
5 years
--
Standardised True Range
240 days
+8.77%
5 years
--
Downside Risk-Adjusted Return
120 days
-35.47%
240 days
-35.47%
Maximum Daily Upside Volatility
60 days
+86.71%
Maximum Daily Downside Volatility
60 days
+57.80%
Liquidity
Average Turnover Rate
60 days
+0.71%
120 days
+1.38%
5 years
--
Turnover Deviation
20 days
-19.05%
60 days
-43.18%
120 days
+10.40%
Peer Comparison
Biotechnology & Medical Research
Pyxis Oncology Inc
PYXS
6.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
